Bax expression is predictive of favorable clinical outcome in chemonaive advanced gastric cancer patients treated with capecitabine, oxaliplatin, and irinotecan regimen1

Translational Oncology

Volumn 5, Issue 3, 2012, Pages 155-159

  Pietrantonio, Filippo ^a   Biondani, Pamela ^a   de Braud, Filippo ^a   Pellegrinelli, Alessandro ^a   Bianchini, Giampaolo ^b   Perrone, Federica ^a   Formisano, Barbara ^a   Di Bartolomeo, Maria ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CAPECITABINE; IRINOTECAN; OXALIPLATIN; PROTEIN BAX;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; CLINICAL ARTICLE; FEMALE; HUMAN; MALE; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; STOMACH CANCER; TREATMENT OUTCOME;

EID: 84862022084     PISSN: None     EISSN: 19365233     Source Type: Journal    
DOI: 10.1596/tlo.12151     Document Type: Article

References (26)

1. Parkin DM (2004). International variation. Oncogene 23, 6329-6340.
2. Grimelius B, Ekstrom K, Hoffman K, Graf W, Sjoden PO, Haglund U, Svensson C, Enander LK, Linne T, Sellstrom H, et al. (1997). Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. Ann Oncol 8, 163-168.
3. Wagner AD, Grothe W, Haerting J, Kleber G, Grothey A, and Fleig WE (2006). Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. J Clin Oncol 24, 2903-2909.
4. Cunningham D, Starling N, Rao S, Iveson T, Nicolson M, Coxon F, Middleton G, Daniel F, Oates J, and Norman AR (2008). Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med 358, 36-46.
5. Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T, et al. (2010). Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 376, 687-697.
6. Bajetta E, Celio L, Ferrario E, Di Bartolomeo M, Denaro A, Dotti K, Mancin M, Bajetta R, Colombo A, and Pusceddu S (2007). Capecitabine plus oxaliplatin and irinotecan regimen every other week: a phase I/II study in first-line treatment of metastatic colorectal cancer. Ann Oncol 18, 1810-1816.
7. Bajetta E, Verzoni E, Ferrario E, Dotti K, Gevorgyan A, and Celio L (2009). Feasibility study of biweekly capecitabine, oxaliplatin, and irinotecan in patients with untreated advanced gastric cancer. Tumori 95, 43-47.
8. Fulda S and Debatin KM (2006). Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy. Oncogene 25, 4798-4811.
9. Miyashita T and Reed JC (1995). Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 80, 293-299.
10. Raffo AJ, Kim AL, and Fine RL (2000). Formation of nuclear bax/p53 complexes is associated with chemotherapy induced apoptosis. Oncogene 19, 6216-6228.
11. Reed JC (2006). Proapoptotic multidomain Bcl-2/Bax-family proteins: mechanisms, physiological roles, and therapeutic opportunities. Cell Death Differ 13, 1378-1386.
12. Siddik ZH (2003). Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 22, 7265-7279.
13. Franceschelli LE, Celio L, Colonna V, Fossile E, Ferrario E, Valente M, Ducceschi M, and Bajetta E (2010). Triplet combination of capecitabine plus oxaliplatin and irinotecan in the treatment of patients with previously untreated advanced gastric cancer (AGC). ESMO Congress. Abstract 721P.
14. Jemal A, Siegel R, Ward E, Hao Y, Xu J, and Thun MJ (2009). Cancer statistics, 2009. CA Cancer J Clin 59, 225-249.
15. Chau I, Norman AR, Cunningham D, Waters JS, Oates J, and Ross PJ (2004). Multivariate prognostic factor analysis in locally advanced and metastatic esophago-gastric cancer-pooled analysis from three multicenter, randomized, controlled trials using individual patient data. J Clin Oncol 22, 2395-2403.
16. Liu HF, Liu WW, Fang DC, and Men RP (1999). Expression and significance of proapoptotic gene Bax in gastric carcinoma. World J Gastroenterol 5, 15-17.
17. Anagnostopoulos GK, Stefanou D, Arkoumani E, Chalkley L, Karagiannis J, Paraskeva K, Mathou N, Dellaporta E, Tsianos E, and Agnantis NJ (2007). Expression of Bax protein in gastric carcinomas. A clinicopathological and immunohistochemical study. Acta Gastroenterol Belg 70, 285-289.
18. Kang SY, Oh YT, Han JH, Choi JH, Lim HY, Kim HI, Lee HW, Jang JH, Park JS, Kim HC, et al. (2006). Concurrent chemoradiotherapy in patients with nasopharyngeal cancer: prognostic significance of low expression of bax. Neoplasma 53, 450-456.
19. Krajewski S, Blomqvist C, Franssila K, Krajewska M, Wasenius VM, Niskanen E, Nordling S, and Reed JC (1995). Reduced expression of proapoptotic gene BAX is associated with poor response rates to combination chemotherapy and shorter survival in women with metastatic breast adenocarcinoma. Cancer Res 55, 4471-4478.
20. Kupryjanczyk J, Szymanska T, Madry R, Timorek A, Stelmachów J, Karpińska G, Rembiszewska A, Ziółkowska I, Kraszewska E, Debniak J, et al. (2003). Evaluation of clinical significance of TP53, BCL-2, BAX and MEK1 expression in 229 ovarian carcinomas treated with platinum-based regimen. Br J Cancer 88, 848-854.
21. Kang SY, Han JH, Lee KJ, Choi JH, Park JI, Kim HI, Lee HW, Jang JH, Park JS, Kim HC, et al. (2007). Low expression of Bax predicts poor prognosis in patients with locally advanced esophageal cancer treated with definitive chemoradiotherapy. Clin Cancer Res 13, 4146-4153.
22. Nakata B, Muguruma K, Hirakawa K, Chung YS, Yamashita Y, Inoue T, Matsuoka T, Onoda N, Kato Y, and Sowa M (1998). Predictive value of Bcl-2 and Bax protein expression for chemotherapeutic effect in gastric cancer: a pilot study. Oncology 55, 543-547.
23. Muguruma K, Nakata B, Hirakawa K, Yamashita Y, Onoda N, Inoue T, Matsuoka T, Kato Y, and Sowa M (1998). p53 and Bax protein expression as predictor of chemotherapeutic effect in gastric carcinoma. Gan To Kagaku Ryoho 25(suppl 3), 400-403.
24. Jeong SH, Han JH, Kim JH, Ahn MS, Hwang YH, Lee HW, Kang SY, Park JS, Choi JH, Lee KJ, et al. (2011). Bax predicts outcome in gastric cancer patients treated with 5-fluorouracil, leucovorin, and oxaliplatin palliative chemotherapy. Dig Dis Sci 56, 131-138.
25. Lee J, Lim T, Uhm JE, Park KW, Park SH, Lee SC, Park JO, Park YS, Lim HY, Sohn TS, et al. (2007). Prognostic model to predict survival following first-line chemotherapy in patients with metastatic gastric adenocarcinoma. Ann Oncol 37, 30-37.
26. Ichikawa W and Sasaki Y (2006). Correlation between tumor response to firstline chemotherapy and prognosis in advanced gastric cancer patients. Ann Oncol 17, 1665-1672.